This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2004 Remove Process Improvement Remove Vaccines
article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

SEPTEMBER 11, 2023

September 2004. Distributed Manufacturing and Point-of-Care Manufacturing of Drugs.” “Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. Journal of Pharmaceutical Sciences 111, no.

Health and Personal Care Stores 52
Health and Personal Care Stores Vaccines Packaging Documentation 52
article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

AUGUST 30, 2022

During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. 6 US Food and Drug Administration. Burke, S., Hammond, and T.

Documentation 52
Documentation FDA Packaging Communication 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024